Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 2/2009

01-04-2009 | Drug Development

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

Author: Prof Roland E. Kontermann

Published in: BioDrugs | Issue 2/2009

Login to get access

Abstract

Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.
Literature
1.
2.
Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechn 2005; 23: 1126–36CrossRef
3.
Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004; 93: 2184–96PubMedCrossRef
4.
Schaller J, Gerber S, Kämpfer U, et al. Human blood plasma proteins: structure and function. West Sussex: John Wiley & Sons, 2008
5.
Keer MA, Thorpe R. Immunochemistry Labfax. Oxford: Blackwell Scientific Publications, 1994; 29
6.
Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5Suppl. 1: S37–47PubMedCrossRef
7.
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmcodynamics. J Pharm Sci 2004; 93: 2645–68PubMedCrossRef
8.
Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137–46PubMedCrossRef
9.
Stork R, Zettlitz KA, Müller D, et al. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283: 7804–12PubMedCrossRef
10.
Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002; 13: 603–8PubMedCrossRef
11.
Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005; 44: 331–47PubMedCrossRef
12.
van de Weert M, Jorgensen L, Moeller EH, et al. Factors of importance for a successful delivery system for proteins. Expert Opin Drug Deliv 2005; 2: 1029–37PubMedCrossRef
13.
Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007; 25: 307–16PubMedCrossRef
14.
Kortt AA, Dolezal O, Power BE, et al. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001; 18: 95–108PubMedCrossRef
15.
Power BE, Shapira DR, Burns JE, et al. Noncovalent scFv multimers of tumor-targeting anti-Lewis Y hu3S193 humanized antibody. Protein Sci 2003; 12: 734–47PubMedCrossRef
16.
Wu AM, Williams LE, Zieran L, et al. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 1999; 4: 47–58
17.
Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C(inH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56: 3055–61PubMed
18.
Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 2001; 12: 220–8PubMedCrossRef
19.
Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405–12PubMedCrossRef
20.
Nielsen UB, Adams GP, Weiner LM, et al. Targeting of bivalent anti-erbB2 diabody antibody fragments to tumor cells is independent of the intrinsic affinity. Cancer Res 2000; 60: 6434–40PubMed
21.
Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 2006; 13: 399–409PubMedCrossRef
22.
Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214–21PubMedCrossRef
23.
24.
Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Del Rev 2002; 54: 459–76CrossRef
25.
Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54: 531–45PubMedCrossRef
26.
Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4168–83CrossRef
27.
Leong SR, DeForge L, Presta L, et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific PEGylation. Cytokine 2001; 16: 106–19PubMedCrossRef
28.
Lu Y, Harding SE, Turner A, et al. Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci 2007; 97: 2062–79CrossRef
29.
Chapman AP, Antoniw P, Spittali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780–3PubMedCrossRef
30.
Krinner EM, Hepp J, Hoffmann P, et al. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentrations. Prot Eng Design Sel 2006; 19: 461–70CrossRef
31.
Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003; 16: 761–70PubMedCrossRef
32.
33.
Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. Int J Colorectal Dis 2008; 23: 289–96PubMedCrossRef
34.
Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther 2004; 20: 1337–46PubMedCrossRef
35.
36.
Gaberc-Porekar V, Zore I, Podobnik B, et al. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Discov Develop 2008; 11: 242–50
37.
Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metabol Dis 2007; 35: 9–16CrossRef
38.
Bendele A, Seely J, Richey C. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998; 42: 152–7PubMedCrossRef
39.
Kim SH, Lee YS, Hwang SY, et al. Effects of PEGyated scFv antibodies against Plasmodium vivax duffy binding protein on the biological activity and stability in vitro. J Microbiol Biotechnol 2007; 17: 1670–7PubMed
40.
Kubetzko S, Sarkar CA, Plückthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005; 68: 1439–54PubMedCrossRef
41.
Cheng TL, Wu PY, Wu MF, et al. Accelerated clearance of polyethylene glycol-modified protiens by anti-polyethylene glycol IgM. Bioconjug Chem 1999; 10: 520–8PubMedCrossRef
42.
Skroda K, Rydlewski J, Langner M, et al. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005; 10: 37–47
43.
Schlapschy M, Theobald I, Mack H, et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Prot Eng Design Sel 2007; 20: 273–84CrossRef
44.
45.
Gregoriadis G, McCormack B, Wang Z, et al. Polysialic acid: potential in drug delivery. FEBS Lett 1993; 315: 271–6PubMedCrossRef
46.
Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm 2005; 300: 125–30PubMedCrossRef
47.
Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 2001; 217: 215–24PubMedCrossRef
48.
Gregoriadis G, Fernandes A, Mital M, et al. Polysialic acid: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci 2000; 57: 1964–9PubMedCrossRef
49.
Jain S, Hreczuk-Hirst DH, McCormack B, et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 2003; 1622: 42–9PubMedCrossRef
50.
Constantinou A, Epenetos AA, Hreczuk-Hirst D, et al. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 2008; 19: 643–50PubMedCrossRef
51.
Besheer A, Hause G, Kressler J, et al. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules 2007; 8: 359–67PubMedCrossRef
52.
Agreda-Vásquez GP, Espinosa-Poblano I, Sánchez-Guerrero SA, et al. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective. J Clin Apher 2008; 23: 163–7PubMedCrossRef
53.
Brecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J Clin Apher 1997; 12: 146–53PubMedCrossRef
54.
55.
Wright A, Morrison SL. Antibody variable region glycosylation: biochemical and clinical effects. Springer Semin Immunopathol 1993; 15: 259–73PubMedCrossRef
56.
57.
Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997; 15: 26–32PubMedCrossRef
58.
Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595–601PubMed
59.
Umaña P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17: 176–80PubMedCrossRef
60.
Ferrara C, Brünker P, Stuter T, et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous b1, 3-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol Bioeng 2006; 93: 851–61PubMedCrossRef
61.
Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII an antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733–40PubMedCrossRef
62.
Wright A, Morrison SL. Effect of altered C(inH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180: 1087–96PubMedCrossRef
63.
Wright A, Sato Y, Okada T, et al. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of different structure. Glycobiology 2000; 10: 1347–55PubMedCrossRef
64.
Newkirk MM, Novick J, Stevenson MM, et al. Different clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 1996; 106: 259–64PubMedCrossRef
65.
Cohen O, Kronman C, Velan B, et al. Amino acid domains control the circulatory residence time of primate acetylcholineesterases in rhesus macaques (Macaca mulatta). Biochem J 2004; 378: 117–28PubMedCrossRef
66.
Meier W, Gill A, Rogge M, et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995; 2: 159–71PubMed
67.
Stockert RJ. The asialoyglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995; 75: 591–609PubMed
68.
Jones AJS, Papac DI, Chin EH, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007; 17: 529–40PubMedCrossRef
69.
Millward TA, Heitzmann M, Bill K, et al. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36: 41–7PubMedCrossRef
70.
Weikert S, Papac D, Briggs J, et al. Engineering chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999; 17: 1116–21PubMedCrossRef
71.
Bragonzi A, Distefano G, Buckburry LD, et al. A new Chinese hamster ovary cell line expressing a2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochim Biophys Acta 2000; 1474: 273–82PubMedCrossRef
72.
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16Suppl. 3: 3–13PubMedCrossRef
73.
Wang M, Lee LS, Nepomich A, et al. Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Eng 1998; 11: 1277–83PubMedCrossRef
74.
Weenen C, Peña JE, Pollak SV, et al. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with O-linked analogs in female rats. J Clin Endocrin Metabol 2004; 89: 5204–12CrossRef
75.
Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005; 15: 5–9PubMedCrossRef
76.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715–25PubMedCrossRef
77.
West AP, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 2000; 39: 9698–708PubMedCrossRef
78.
Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of g-globulin in humans. Int Immunol 2001; 13: 993–1002PubMedCrossRef
79.
Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281: 23514–24PubMedCrossRef
80.
Andersen JT, Qian JD, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36: 3044–51PubMedCrossRef
81.
Chaudhury C, Brooks CL, Carter DC, et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006; 45: 4983–90PubMedCrossRef
82.
Martin WL, West AP, Gan L, et al. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7: 867–77PubMedCrossRef
83.
Vaughn DE, Milburn CM, Penny DM, et al. Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol 1997; 274: 597–607PubMedCrossRef
84.
Raghavan M, Bonagura VR, Morrison SL, et al. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995; 34: 14649–57PubMedCrossRef
85.
Medesan C, Matesoi D, Radu C, et al. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol 1997; 158: 2211–7PubMed
86.
87.
Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20: 460–70PubMedCrossRef
88.
Lazar GA, Dang W, Karki S, et al. Engineering antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103: 4005–10PubMedCrossRef
89.
Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571–5PubMed
90.
Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15: 637–40PubMedCrossRef
91.
Hinton PR, Johlfs MG, Xiong JM, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279: 6213–6PubMedCrossRef
92.
Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176: 346–56PubMed
93.
Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18: 1759–69PubMedCrossRef
94.
Gurbaxani B, Dela Cruz LL, Chitalacharuvu K, et al. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43: 1462–73PubMedCrossRef
95.
Datta-Mannan A, Witcher DR, Tang Y, et al. Monoclonal antibody clearance: impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282: 1709–17PubMedCrossRef
96.
Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23: 1283–8PubMedCrossRef
97.
Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoem-bryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65: 622–31PubMed
98.
Dall’Acqua WF, Woods RM, Ward ES, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169: 5171–80PubMed
99.
Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008; 22: 11–26PubMedCrossRef
100.
Colcher D, Pavlinkova G, Beresford G, et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998; 42: 225–41PubMed
101.
Holliger P, Wing M, Pound JD, et al. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 1997; 15: 632–6PubMedCrossRef
102.
Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9: 319–26PubMed
103.
Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197: 315–22PubMedCrossRef
104.
Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19: 569–77PubMedCrossRef
105.
Smith BJ, Popplewell A, Athwal D, et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001; 12: 750–6PubMedCrossRef
106.
Müller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282: 12650–60PubMedCrossRef
107.
Balan V, Nelson DR, Sulkowski MS, et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon a fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antivir Ther 2006; 11: 35–45PubMed
108.
Yazaki PJ, Kassa T, Cheung C, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008; 35: 151–8PubMedCrossRef
109.
Sung C, Nardelli B, Lafleur DW, et al. An IFN-β-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res 2003; 23: 25–36PubMedCrossRef
110.
Melder RJ, Osborn BL, Riccobene T, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein. Cancer Immunol Immunother 2005; 54: 535–47PubMedCrossRef
111.
Kraulis PJ, Jonasson P, Nygren PA, et al. The serum albumin-binding domain of streptococcal protein G is a three-helix bundle: a heteronuclear NMR study. FEBS Lett 1996; 378: 190–4PubMedCrossRef
112.
Linhult M, Binz HK, Uhlén M, et al. Mutational analysis of the interaction between albumin-binding domain fromo streptococcal protein G and human serum albumin. Protein Sci 2002; 11: 206–13PubMedCrossRef
113.
Johannson MU, Frick IM, Nilsson H, et al. Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 2002; 277: 8114–29CrossRef
114.
Stork R, Müller D, Kontermann R. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcus protein G. Prot Eng Design Sel 2007; 20: 569–76CrossRef
115.
Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Develop 2007; 10: 167–75
116.
Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007; 67: 2773–82PubMedCrossRef
117.
Jonsson A, Dogan J, Herne N, et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Prot Eng Design Sel 2008; 21: 517–27
118.
Libon C, Corvaia N, Haeuw JF, et al. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine 1999; 17: 406–14PubMedCrossRef
119.
Sato AK, Sexton DJ, Morganelli LA, et al. Development of mammalian serum albumin affinity purification media by peptide phage display. Biotechnol Prog 2002; 18: 182–92PubMedCrossRef
120.
Dennis MS, Zhang M, Meng G, et al. Albumin binding as a general strategy for improving pharmacokinetics of proteins. J Biol Chem 2002; 277: 35035–40PubMedCrossRef
121.
Bessette PH, Rice JL, Daugherty PS. Rapid isolation of high-affinity protein binding peptides using bacterial display. Prot Eng Design Sel 2004; 17: 731–9CrossRef
122.
Nguyen A, Reyes II AE, Zhang M, et al. The pharmacokinetics of an albuminbinding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Prot Eng Design Sel 2006; 19: 291–7CrossRef
123.
sRoovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol Immunother 2007; 56: 303–17CrossRef
124.
Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002; 98: 456–62PubMedCrossRef
125.
Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008; 7: 2288–97PubMedCrossRef
126.
Holt LJ, Herring C, Jespers LS, et al. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21: 484–90PubMedCrossRef
127.
Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Prot Eng Design Sel 2008; 21: 283–8CrossRef
128.
Bhattacharya AA, Grüne T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000; 303: 721–32PubMedCrossRef
129.
Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498–504PubMedCrossRef
130.
Dumelin CE, Rüssel S, Buller F, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl 2008; 47: 3196–201PubMedCrossRef
Metadata
Title
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Author
Prof Roland E. Kontermann
Publication date
01-04-2009
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 2/2009
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200923020-00003

Other articles of this Issue 2/2009

BioDrugs 2/2009 Go to the issue

Therapy Review

Biologic Therapy for Rheumatoid Arthritis

Adis Drug Profile

Golimumab

Drug Development

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

Leading Article

Targeted Therapy for Kaposi Sarcoma